Leqvio (Inclisiran) and Prednisone Interaction

Why This Combination Raises Questions

Patients on inclisiran for atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) frequently require prednisone courses for inflammatory conditions, autoimmune flares, or chronic obstructive pulmonary disease exacerbations. The concern is straightforward: prednisone is known to worsen the same lipid parameters that inclisiran is prescribed to improve.

Inclisiran received FDA approval in December 2021 as a first-in-class small interfering RNA (siRNA) targeting hepatic PCSK9 production [1]. Its unique mechanism, a subcutaneous injection given just twice yearly after an initial dose at month three, makes it different from every other lipid-lowering agent on the market. Prednisone, a synthetic glucocorticoid used across dozens of indications, carries a well-documented metabolic side-effect profile that includes dyslipidemia, insulin resistance, and weight gain [2]. Understanding how these two drugs interact requires examining both the pharmacokinetic and pharmacodynamic layers.

Pharmacokinetic Profile: No CYP450 Overlap

Inclisiran does not compete with prednisone for any shared metabolic pathway. That single fact eliminates the most common source of drug-drug interactions.

According to the Leqvio FDA prescribing information, inclisiran is not a substrate, inhibitor, or inducer of CYP450 enzymes or common drug transporters such as P-glycoprotein (P-gp), OATP1B1, or OATP1B3 [1]. Inclisiran is metabolized by ribonucleases into inactive nucleotide fragments. This process occurs intracellularly via the RNA-induced silencing complex (RISC), a mechanism entirely separate from traditional hepatic drug metabolism [3].

Prednisone is a prodrug converted to prednisolone by hepatic 11-beta-hydroxysteroid dehydrogenase. Prednisolone undergoes CYP3A4-mediated oxidation and is a substrate of P-gp [2]. Because inclisiran neither inhibits nor induces CYP3A4 or P-gp, it will not alter prednisone plasma concentrations. The reverse is also true: prednisone cannot accelerate or slow inclisiran's degradation because RISC-mediated cleavage is independent of CYP enzyme activity.

The ORION-1 phase II trial (N=501) enrolled patients on a range of concomitant medications and found no clinically meaningful pharmacokinetic interactions with inclisiran [4]. No formal interaction study with glucocorticoids has been conducted, but the siRNA mechanism makes such a study pharmacologically unnecessary.

Pharmacodynamic Opposition: The Real Clinical Issue

Where the concern lies is not in how the drugs are metabolized but in what they do to lipid levels once in the body. Prednisone directly opposes inclisiran's therapeutic goal.

Glucocorticoids stimulate hepatic very-low-density lipoprotein (VLDL) production, increase free fatty acid flux from adipose tissue, and reduce LDL receptor expression [5]. A systematic review published in the Journal of Clinical Endocrinology & Metabolism found that glucocorticoid use at doses equivalent to prednisone 10 mg/day or higher raised total cholesterol by 5-15% and LDL-C by a similar margin within 1-4 weeks of initiation [6]. Higher doses (≥20 mg/day) produced more pronounced lipid elevations and triglyceride increases exceeding 20% in some cohorts.

Inclisiran, by contrast, reduced LDL-C by 50-52% from baseline at day 510 in the key ORION-10 (N=1,561) and ORION-11 (N=1,617) trials, with consistent effects maintained across biannual dosing intervals [7]. The drug achieves this by silencing PCSK9 messenger RNA in hepatocytes, leading to increased LDL receptor recycling and enhanced LDL-C clearance from circulation.

The conflict is clear: prednisone downregulates LDL receptors; inclisiran upregulates them. If a patient starts prednisone 20 mg/day while on inclisiran, the net LDL-C reduction may fall from the expected 50% to 35-45%, depending on the glucocorticoid dose and duration. This attenuation is clinically relevant for patients near their LDL-C goal but unlikely to negate inclisiran's benefit entirely.

Glucose and Metabolic Monitoring

Prednisone-induced hyperglycemia is one of the most common reasons patients on this combination require additional surveillance. The mechanism is separate from the lipid interaction but compounds overall cardiometabolic risk.

Glucocorticoids impair insulin sensitivity in skeletal muscle and liver while simultaneously increasing hepatic gluconeogenesis [8]. A prospective cohort study in Diabetes Care (N=128,194) found that oral glucocorticoid users had a 2.23-fold increased risk of developing new-onset diabetes compared to non-users (hazard ratio 2.23; 95% CI 2.10-2.37) [9]. Even short courses of 5-7 days raised fasting glucose by 10-20 mg/dL in patients without pre-existing diabetes.

Inclisiran has no direct effect on glucose metabolism. In ORION-10 and ORION-11, HbA1c changes were comparable between inclisiran and placebo arms [7]. The concern is not that inclisiran worsens glucose control but that clinicians may underestimate prednisone's metabolic impact in patients whose primary focus is lipid management.

For patients with type 2 diabetes already on inclisiran, adding prednisone demands glucose monitoring at minimum every 2-3 days during the first two weeks, with adjustment of diabetes medications as needed. The American Diabetes Association recommends a stepwise insulin dose escalation protocol for steroid-induced hyperglycemia, preferring intermediate-acting insulin (NPH) timed to match prednisone's pharmacodynamic peak at 4-8 hours post-dose [10].

Bone and Cardiovascular Risk Overlap

Both ASCVD and chronic glucocorticoid use independently increase fracture risk, creating a compounded concern in patients receiving both inclisiran and prednisone long-term.

Prednisone at doses ≥7.5 mg/day for three or more months triggers glucocorticoid-induced osteoporosis (GIO), the most common form of secondary osteoporosis [11]. The American College of Rheumatology 2022 guidelines recommend bone-density screening and fracture-risk assessment for any patient expected to receive glucocorticoids for ≥3 months [12]. Inclisiran itself has shown no signal for bone loss. In ORION-9 (N=482, HeFH population), musculoskeletal adverse events occurred at rates similar to placebo [13].

The practical takeaway: patients on long-term prednisone and inclisiran should have their FRAX score calculated, vitamin D and calcium levels checked, and bone-protective therapy considered independently of their lipid management plan.

Infection Susceptibility Considerations

Prednisone's immunosuppressive effects are well established. Doses exceeding 20 mg/day significantly impair T-cell function and increase susceptibility to opportunistic infections [2]. Some clinicians have asked whether inclisiran's injection-site immune reactions could be amplified or masked by concurrent glucocorticoid therapy.

The ORION program reported injection-site reactions in 5.0% of inclisiran-treated patients versus 0.7% on placebo, with reactions described as mild and self-limiting [7]. These reactions are thought to involve local innate immune recognition of the siRNA molecule. Theoretically, systemic glucocorticoids could blunt this local response. No clinical data exist to confirm or deny this hypothesis, but the practical significance is minimal: injection-site reactions with inclisiran are already mild and rarely lead to discontinuation (0.2% discontinuation rate in ORION-10).

More relevant is the broader immunosuppressive context. Patients on prednisone doses ≥20 mg/day should be current on vaccinations and monitored for signs of infection. This is standard glucocorticoid management, unrelated to inclisiran specifically, but worth reinforcing during medication review.

Dosing and Administration: No Adjustments Needed

Neither drug requires dose modification when co-administered. This is one of the simpler aspects of the combination.

Inclisiran dosing is fixed: 284 mg subcutaneously at day 0, day 90, and every 6 months thereafter [1]. There is no renal-dose adjustment needed for eGFR ≥15 mL/min/1.73 m², and mild-to-moderate hepatic impairment does not alter dosing. Prednisone dosing varies by indication, and its dose and taper schedule should be determined by the condition being treated, not by the presence of inclisiran in the regimen.

One practical timing note: if a prednisone course is expected to last less than 4 weeks, the transient lipid elevation may not warrant re-checking lipids or reconsidering the inclisiran dosing schedule. For courses lasting 4 weeks or longer, a repeat fasting lipid panel at 4-8 weeks into the steroid course provides actionable data about whether additional lipid therapy (e.g., ezetimibe add-on) is warranted.

When To Involve the Prescriber

Most patients can take inclisiran and prednisone together without difficulty. There are specific scenarios that warrant a conversation with the prescribing physician.

A patient whose LDL-C was at goal on inclisiran alone but rises above target after starting prednisone needs reassessment. If prednisone is expected to continue for months, adding ezetimibe (10 mg/day) or uptitrating statin therapy may restore LDL-C to goal without altering the inclisiran schedule. The 2018 AHA/ACC cholesterol guideline recommends maximizing non-statin therapies when LDL-C remains ≥70 mg/dL in very-high-risk ASCVD patients [14].

Patients with pre-existing diabetes who start high-dose prednisone (≥40 mg/day) while on inclisiran should have endocrinology or primary care involvement for glucose management. The lipid interaction is secondary to the metabolic destabilization that high-dose steroids produce.

For patients on chronic low-dose prednisone (≤5 mg/day), as commonly used in rheumatoid arthritis or adrenal insufficiency, the lipid impact is minimal and routine monitoring (annual or biannual lipid panels timed with inclisiran dosing visits) is sufficient.

Monitoring Schedule for Co-Administration

A structured monitoring plan minimizes risk and keeps both drugs working effectively. The schedule below applies to patients starting prednisone while already on stable inclisiran therapy.

Baseline (before prednisone starts): Fasting lipid panel, fasting glucose or HbA1c, basic metabolic panel, blood pressure.

Week 2-4 of prednisone: Fasting glucose check (daily self-monitoring if diabetic). Assess for edema, blood pressure elevation, and mood changes.

Week 4-8: Repeat fasting lipid panel. Compare LDL-C to pre-steroid baseline. If LDL-C has risen >15% above goal, consider adding ezetimibe or adjusting statin dose.

Every 3 months while prednisone continues: Repeat lipid panel, glucose/HbA1c, and assess steroid taper feasibility. Align lipid monitoring with inclisiran injection visits where possible.

After prednisone discontinuation: Lipid panel at 4-6 weeks post-taper to confirm return to baseline LDL-C on inclisiran monotherapy.

Patient Counseling Points

Patients should understand three things about this combination. First, the two drugs do not "clash" in the traditional sense. There is no dangerous reaction or need to separate doses by hours. Second, prednisone may temporarily raise cholesterol, which can make it seem like Leqvio "stopped working." It hasn't. The steroid is simply pushing lipids in the opposite direction. Third, blood sugar monitoring matters. Even patients who have never had diabetes can develop steroid-induced hyperglycemia, and those already managing diabetes should expect to need medication adjustments.

Patients should report any persistent fasting blood sugar readings above 180 mg/dL, sudden weight gain exceeding 5 pounds in a week, or new ankle swelling while on the combination. These symptoms may indicate prednisone-related fluid retention or metabolic changes that need clinical attention.

The twice-yearly Leqvio injection schedule does not change because of prednisone. Patients should keep their scheduled injection appointments regardless of steroid status. If an injection is due during a prednisone taper, it should still be administered on time.